Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna
, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS) announced it will be a key sponsor of the National Multiple Sclerosis Society’s
series of events being held in the Houston area and Austin, Texas, during October and November.
This marks the third consecutive year the Company has been a key supporter of the Walk MS events. Walk MS connects people living with MS and those who care about them. The events raise funds and give hope to the more than 2.1 million people living with MS worldwide. Since 1988, Walk MS has raised more than $770 million to support life changing programs and cutting-edge research and development of new therapies.
“Opexa is proud to be a sponsor of the National MS Society’s Walk MS program,” stated Neil K. Warma, Opexa's President and Chief Executive Officer. “It is a wonderful opportunity for everyone in the Company to interact with and enjoy the company of many individuals with MS and their families. We take pride in our work developing a personalized immunotherapy for Secondary Progressive MS, and we receive so much motivation from the people living with the disease and their families. The National MS Society works tirelessly to drive change through advocacy, facilitates professional education and provides programs and services to help people with MS move their lives forward. These events play a pivotal role in raising funds that directly benefit MS patients and their families, as well as raise awareness of the disease and the impact it has on people's lives.”
Opexa also wants to remind participants that there will be a donation drop off location for the events at the Opexa offices in The Woodlands the evening of October 23
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.